ClinicalTrials.gg

Program

Radiosensitizer VS-101

Also written as “VS-101”, “VS101 Insert Dose A” and “VS101 Insert Dose B”.

Its studies are mostly in Neoplasms, Squamous Cell · Glaucoma, Open-Angle, led by 2 companies.

Furthest: phase 2, since Apr 30, 20142 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ViSci10 open or runningphase 2since Apr 30, 2014Apr 30, 2014none ahead
VSPharmTech11 open or runningphase 2since Apr 16, 2025Apr 16, 2025Dec 2027phase 2 · NCT06959082

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 30, 2014First study: phase 2 study in Glaucoma, Open-AngleNew to ViSciViSci · NCT02129673 · 77 enrolled · United States
  2. Apr 16, 2025VSPharmTech’s first study: phase 2 study in Head and Neck Cancer Squamous Cell CarcinomaNew to VSPharmTechVSPharmTech · NCT06959082 · 30 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 2 study in Head and Neck Cancer Squamous Cell CarcinomaVSPharmTech · NCT06959082

TargetBeta

ROS1 →read by rule
“An orally bioavailable inhibitor of survivin and generator of reactive oxygen species (ROS), ”NCIt, by rule

Other programs on ROS1

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
taletrectinibruleNuvation Biophase 311
repotrectinibruleBristol-Myers Squibbphase 39
Fudotinibruleguangzhou-joyo-pharma-co-ltdphase 33
Cross-over to JYP0322ruleguangzhou-joyo-pharma-co-ltdphase 31
ROS1/NTRK Inhibitor ANS03ruleavistone-biotechnology-co-ltdphase 11
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06959082Head and Neck Cancer Squamous Cell Carcinoma · United States2RecruitingVSPharmTechDec 202730
NCT02129673Glaucoma, Open-Angle · United States2CompletedViSciMay 201777

How it is read

Names in the registry

  • “VS-101”, 1 entry
  • “VS101 Insert Dose A”, 1 entry
  • “VS101 Insert Dose B”, 1 entry
  • “VS101 Insert Dose C”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.